Alaunos Therapeutics (TCRT) Reports Q3, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives Nov 14, 2023 07:31AM
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives Nov 14, 2023 07:30AM
Alaunos Therapeutics (TCRT) to wind down its TCR-T Library Phase 1/2 trial and prioritize the hunTR platform Aug 14, 2023 04:07PM
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives Aug 14, 2023 04:05PM
Alaunos Therapeutics (TCRT) Prices Public Offering of Common Stock for Gross Proceeds of Approximately $15.7 Million Nov 29, 2022 09:03AM


Nov 29, 2022 09:01AM Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
Nov 28, 2022 04:01PM Alaunos Therapeutics (TCRT) Announces Proposed Public Offering of Common Stock
Nov 28, 2022 04:01PM Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
Jul 15, 2022 06:55AM Cantor Fitzgerald Assumes Alaunos Therapeutics Inc. (TCRT) at Overweight